Hyung-Don Kim
University of Ulsan
H-index: 18
Asia-South Korea
Top articles of Hyung-Don Kim
Clinical Outcomes of Small Cell Carcinoma of the Genitourinary Tract and the Prognostic Significance of the Tumor Immune Microenvironment
Cancer Research and Treatment: Official Journal of Korean Cancer Association
2024/4
Hyung-Don Kim
H-Index: 8
Prognostic value of mismatch repair deficiency in patients receiving first-line fluoropyrimidine plus platinum for metastatic, recurrent, or unresectable gastric cancer
European Journal of Surgical Oncology
2020/1/1
Regorafenib plus nivolumab in unresectable hepatocellular carcinoma: the phase 2 RENOBATE trial
Nature Medicine
2024/2/19
Results from a phase 2 study of triplet blockade of the IL-27, PD-(L) 1, and VEGF pathways with casdozokitug (casdozo, SRF388) in combination with atezolizumab (atezo) and …
2024/1/20
Second-line regorafenib in patients (pts) with unresectable hepatocellular carcinoma (uHCC) after progression on first-line atezolizumab plus bevacizumab (Atezo-Bev): Phase 2 …
2024/1/20
Changhoon Yoo
H-Index: 23
Hyung-Don Kim
H-Index: 8
Predictive role of homologous recombination deficiency (HRD) for irinotecan in combination with venadaparib, a novel PARP1/2 inhibitor, as third-or fourth-line treatment in …
2024/1/20
Hyung-Don Kim
H-Index: 8
Ji-Won Kim
H-Index: 13
Organ-specific response with first-line atezolizumab-bevacizumab versus lenvatinib for patients with advanced hepatocellular carcinoma
Hepatology International
2024/1/12
Artificial intelligence-powered spatial analysis of tumor-infiltrating lymphocytes as a predictive biomarker for immune checkpoint inhibitors in advanced biliary tract cancer
2024/1/10
Clinical outcomes of Epstein–Barr virus (EBV)-associated metastatic and locally advanced unresectable gastric cancers (GCs) in patients receiving first-line fluoropyrimidine …
Gastric Cancer
2024/1
GASTric Cancer HER2 Re-Assessment Study 2 (GASTHER2): HER2 Re-assessment for Initially HER2-Negative Advanced Gastric Cancer Patients after Progression on First-Line Treatment
Cancer Research and Treatment: Official Journal of Korean Cancer Association
2024/1
Hyung-Don Kim
H-Index: 8
Yoon-Koo Kang
H-Index: 56
DNA mismatch repair deficiency and outcomes of patients with locally advanced gastric cancer treated with preoperative docetaxel, oxaliplatin, and S-1 plus surgery and …
Gastric Cancer
2024/1
Discordant PD-L1 results between 28–8 and 22C3 assays are associated with outcomes of gastric cancer patients treated with nivolumab plus chemotherapy
Gastric Cancer
2024/4/22
Hyung-Don Kim
H-Index: 8
Impact of systemic steroids on the efficacy of first line imatinib treatment of patients with advanced gastrointestinal stromal tumors (GISTs)
2024/4/8
RO7119929, a TLR7 agonist prodrug, induces local inflammation of the tumor microenvironment (TME) by reprogramming myeloid cells in patients (pts) with advanced primary or …
Cancer Research
2023/4/4
Erratum: Korean Practice Guidelines for Gastric Cancer 2022: An Evidence-based, Multidisciplinary Approach
2023/4/1
Epithelial–mesenchymal transition phenotype and peritumoral immune cell infiltration in advanced biliary tract cancer
Anticancer Research
2023/2/1
Phase II study of the combination of durvalumab, tremelimumab, and paclitaxel as second-line chemotherapy in biomarker-selected patients with metastatic gastric cancer.
2023/2/1
A phase 2 study of durvalumab plus DOS (docetaxel, oxaliplatin, S-1) neoadjuvant chemotherapy followed by surgery and adjuvant durvalumab plus S-1 chemotherapy in patients with …
2023/2/1
Hyung-Don Kim
H-Index: 8
Yoon-Koo Kang
H-Index: 56
Efficacy and safety of lenvatinib in patients with recurrent hepatocellular carcinoma after liver transplantation
Cancer Medicine
2023/2
Dynamic changes in peripheral blood monocytes early after anti-PD-1 therapy predict clinical outcomes in hepatocellular carcinoma
Cancer Immunology, Immunotherapy
2023/2
Co-Authors
